Table 4.
Total number of live births | Preterm delivery | SGA | Caesarean section | ||||
---|---|---|---|---|---|---|---|
N (%)a | OR (95% CI) | N (%)b | OR (95% CI) | N (%)c | OR (95% CI) | ||
Controls | 651 | 31 (4.8) | Ref. | 61 (9.8) | Ref. | 77 (12.3) | Ref. |
Survivors | 592 | 57 (9.8) | 2.0 (1.2–3.5)d | 59 (10.7) | 1.1 (0.7–1.7)d | 108 (19.2) | 1.8 (1.2–2.6)d |
Model 1: Type of diagnosisd | |||||||
Controls | 651 | 31 (4.8) | Ref. | 61 (9.8) | Ref. | 77 (12.3) | Ref. |
Leukaemia | 191 | 13 (7.0) | 1.4 (0.6–2.9) | 16 (9.0) | 0.8 (0.4–1.5) | 35 (19.3) | 1.8 (1.1–3.0) |
Lymphoma | 134 | 12 (9.2) | 1.7 (0.7–3.7) | 11 (8.7) | 0.8 (0.4–1.7) | 16 (12.6) | 0.9 (0.5–1.9) |
CNS tumours | 25 | 4 (16.0) | – | 4 (17.4) | – | 6 (24.0) | 2.2 (0.7–4.6) |
Neuroblastoma and other peripheral nervous cell tumours | 45 | 2 (4.4) | – | 8 (19.0) | 2.4 (1.1–5.3) | 8 (18.6) | 1.9 (0.8–4.6) |
Renal tumours | 53 | 10 (18.9) | 4.9 (2.1–11.6) | 3 (6.0) | – | 12 (24.0) | 2.7 (1.2–6.1) |
Bone tumours | 61 | 7 (11.9) | 2.8 (1.1–7.0) | 8 (14.0) | 1.7 (0.7–4.0) | 14 (24.1) | 2.3 (1.1–5.1) |
Soft tissue sarcoma | 43 | 7 (16.3) | 4.0 (1.3–12.6) | 7 (17.5) | 2.0 (0.7–5.8) | 13 (31.7) | 3.4 (1.4–8.4) |
Germ cell tumours | 21 | 1 (4.8) | – | 1 (4.8) | – | 2 (9.5) | – |
Other | 19 | 1 (5.3) | – | 1 (5.3) | – | 2 (10.5) | – |
Model 2: Age at diagnosis (years)d | |||||||
Controls | 651 | 31 (4.8) | Ref. | 61 (9.8) | Ref. | 77 (12.3) | Ref. |
< 10 | 332 | 38 (11.7) | 2.5 (1.4–4.4) | 31 (10.0) | 1.0 (0.6–1.6) | 68 (21.4) | 2.1 (1.4–3.2) |
≥ 10 to< 13 | 105 | 9 (8.7) | 1.9 (0.8–4.5) | 12 (12.0) | 1.2 (0.6–2.6) | 15 (15.3) | 1.4 (0.7–2.9) |
≥ 13 | 155 | 10 (6.7) | 1.3 (0.5–3.4) | 16 (11.5) | 1.2 (0.6–2.5) | 25 (17.1) | 1.4 (0.8–2.6) |
Model 3: CED scoree | |||||||
Controls | 651 | 31 (4.8) | Ref. | 61 (9.8) | Ref. | 77 (12.3) | Ref. |
0 | 301 | 28 (9.6) | 1.9 (1.0–3.6) | 23 (8.3) | 0.8 (0.5–1.4) | 57 (19.5) | 2.0 (1.2–3.1) |
> 0 to ≤ 4000 mg/m2 | 78 | 6 (7.7) | 1.1 (0.4–3.1) | 11 (15.1) | 1.5 (0.6–3.9) | 15 (21.4) | 2.1 (1.0–4.4) |
> 4000 to ≤ 8000 mg/m2 | 82 | 12 (14.8) | 3.0 (1.3–7.4) | 9 (11.4) | 1.2 (0.5–2.6) | 24 (30.0) | 2.9 (1.5–5.6) |
> 8000 mg/m2 | 114 | 10 (8.8) | 1.6 (0.7–3.6) | 14 (13.0) | 1.4 (0.7–2.8) | 12 (11.5) | 0.8 (0.4–1.8) |
Model 4: Radiotherapy body sitef | |||||||
Controls | 651 | 31 (4.8) | Ref. | 61 (9.8) | Ref. | 77 (12.3) | Ref. |
No RT | 305 | 28 (9.4) | 2.1 (1.0–4.3) | 19 (6.6) | 0.5 (0.3–1.0) | 45 (15.8) | 1.6 (0.9–2.7) |
Cranial/spinal RT | 141 | 14 (10.1) | 2.1 (1.0–4.5) | 19 (15.0) | 1.2 (0.6–2.3) | 36 (26.1) | 2.8 (1.5–5.0) |
Lower abdominal/pelvic RT | 54 | 8 (14.8) | 4.0 (1.6–10.1) | 4 (8.3) | – | 11 (21.2) | 2.1 (0.9–5.2) |
TBI | 2 | 1 (50.0) | – | 1 (50.0) | – | 0 | – |
Other RT | 86 | 6 (7.2) | 1.6 (0.6–4.6) | 15 (18.8) | 1.5 (0.6–3.7) | 15 (18.3) | 1.9 (0.9–4.2) |
Model 5: Stem cell transplantation | |||||||
Controls | 651 | 31 (4.8) | Ref. | 61 (9.8) | Ref. | 77 (12.3) | Ref. |
No | 577 | 56 (9.9) | 2.1 (1.2–3.6) | 57 (10.6) | 1.1 (0.7–1.7) | 106 (19.3) | 1.8 (1.2–2.6) |
Yes | 6 | 0 | – | 0 | – | 1 (16.7) | – |
Values represent the number (%) of women, unless indicated otherwise. The subcategories may not add up to the total number of women due to missing values
CED cyclophosphamide equivalent dose, CNS central nervous system, RT radiotherapy, SGA small for gestational age, TBI total body irradiation
aPercentage of the live births for whom the gestational week was known
bPercentage of the live births for whom SGA could be calculated
cPercentage of the live births for whom the method of delivery was known
dCorrected for age at time of pregnancy and educational level
eCorrected for age at time of pregnancy, educational level, and gonadotoxic radiotherapy (i.e. lower abdominal/pelvic RT and/or TBI) (yes or no)
fCorrected for age at time of pregnancy, educational level, and alkylating agent therapy (yes or no)